Potential value of mitochondrial regulatory pathways in the clinical application of clear cell renal cell carcinoma:
Xiaochen Qi1, Yangyang Ge2, Ao Yang1
1Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.
Background:
Renal clear cell carcinoma (RCC) is a common cancer in urinary system with increasing incidence. At present, targeted therapy and immunotherapy are the main therapeutic programs in clinical therapy. To develop novel drugs and provide new ideas for clinical therapy, the identification of potential ccRCC subtypes and potential target genes or pathways has become a current research focus.
Aim:
The aim of this study was to explore the underlying mechanisms of mitochondrial function in ccRCC. This regulatory pathway is closely related to tumor development and metastasis in ccRCC patients, and their abnormal changes may affect the prognosis of cancer patients. Therefore, we decided to construct a prognostic model of ccRCC patients based on mitochondrial regulatory genes, aiming to provide new methods and ideas for clinical therapy.
Result:
The 5-year survival prediction model based on iterative LASSO reached 0.746, and the cox model based on coxph reached C-index = 0.77, integrated c/D AUC = 0.61, and integrated brier score = 0.14. The rsf model based on randomForestSRC was built with C-index = 0.82, integrated c/D AUC = 0.69, and integrated brier score = 0.11. The results show that mitochondrial regulatory pathway is a potential target pathway for clinical therapy of ccRCC, which can provide guidelines for clinical targeted therapy, immunotherapy and other first-line therapy.
Insights
This study developed prognostic models for clear cell renal cell carcinoma (ccRCC) using mitochondrial regulatory genes. These models show promise for guiding targeted therapy and immunotherapy in ccRCC patients.
Area of Science:
- Oncology
- Genetics
- Mitochondrial Biology
Background:
- Renal clear cell carcinoma (ccRCC) incidence is rising globally.
- Current treatments for ccRCC include targeted therapy and immunotherapy.
- Identifying novel therapeutic targets and subtypes is crucial for advancing ccRCC treatment.
Purpose of the Study:
- To investigate the role of mitochondrial function in ccRCC development and metastasis.
- To construct a prognostic model for ccRCC patients utilizing mitochondrial regulatory genes.
- To offer new therapeutic strategies for ccRCC.
Main Methods:
- Utilized iterative LASSO, coxph, and randomForestSRC (rsf) models for survival prediction.
- Developed a prognostic model based on mitochondrial regulatory genes.
- Evaluated model performance using C-index, integrated c/D AUC, and integrated Brier score.
Main Results:
- The rsf model demonstrated strong predictive performance (C-index=0.82, integrated c/D AUC=0.69).
- The cox model also showed good predictive accuracy (C-index=0.77, integrated c/D AUC=0.61).
- Mitochondrial regulatory pathways emerged as potential therapeutic targets for ccRCC.
Conclusions:
- Mitochondrial regulatory genes can be used to build effective prognostic models for ccRCC.
- The identified mitochondrial pathways offer potential targets for ccRCC therapies.
- Findings provide a basis for refining clinical management of ccRCC.
